A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 599 participants.
Also called NCT01624259
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 599 participants
- Sponsor
- Registry
-
NCT01624259 -
2011-003810-18
-
- Other papers using this trial's data
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Germany, Hungary, Mexico, Poland, Puerto Rico, Romania, Slovakia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01624259. Randomized; no masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-11 (actual). Results posted on 2014-10-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
- Acronym
- AWARD-6
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- LY2189265
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- Metformin
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01624259- Content hash
d045b96823f367b7c12b83aab9f5f756e3fd9e30dd68df542d2f9d6922188476